Core Viewpoint - Fosun Pharma's subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has had its drug registration application for Cisplatin Injection accepted by the National Medical Products Administration, indicating progress in the development of this self-developed chemical drug for treating metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer [1]. Group 1 - The drug in question, Cisplatin Injection, is developed by the company and is intended for the treatment of specific types of cancer [1]. - The acceptance of the drug registration application marks a significant milestone for the company in expanding its oncology product portfolio [1].

证券代码：600196 股票简称：复星医药 编号：临 2026-024 上海复星医药（集团）股份有限公司 关于控股子公司药品注册申请获受理的公告 根据 IQVIA CHPA 最新数据 1，2024 年，顺铂注射液于中国境内（不包括港澳台 地区）的销售额约为人民币 1.65 亿元。 三、对上市公司的影响及风险提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公 司吉斯美（武汉）制药有限公司就顺铂注射液（以下简称"该药品"）的药品注册 申请获国家药品监督管理局受理。 二、该药品的基本信息及研究情况 该药品为本集团（即本公司及控股子公司/单位，下同）自主研发的化学药品， 拟用于治疗转移性睾丸肿瘤、转移性卵巢肿瘤、晚期膀胱癌。 截至 2026 年 1 月，本集团现阶段针对该药品的累计研发投入约为人民币 469 万 元（未经审计）。 1 特此公告。 上海复星医药（集团）股份有限公司 董事会 二零二六年二月十三日 2 该药品在进行商业化生产前，尚需（其中主要包 ...

近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子 公司锦州奥鸿药业有限责任公司就盐酸莫托咪酯注射液（项目代号：ET-26，申 请注册分类：化药 1 类；以下简称"该新药"）的药品注册申请获国家药品监督 管理局受理，本次申报拟定适应症为用于麻醉诱导和短时手术麻醉。 二、该新药的基本信息及研究情况 上海复星医药（集团）股份有限公司 关于控股子公司药品注册申请获受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 证券代码：600196 股票简称：复星医药 编号：临 2026-023 该新药是咪唑类改构的静脉全身麻醉 1 类新药，于 2014 年被列入"重大新 药创制"科技重大专项。 截至 2026 年 1 月，本集团（即本公司及控股子公司/单位，下同）现阶段针 对该新药的累计研发投入约为人民币 1.89 亿元（未经审计）。 根据 IQVIA CHPA 最新数据1，2024 年，用于麻醉诱导及短时手术麻醉的同 类药物（依托咪酯等）于中国境内（不包含港澳台地区）的销售额约为人民币 42.38 亿元。 ...

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received acceptance from the National Medical Products Administration for the drug registration application of Mivacurium Hydrochloride Injection, aimed at anesthesia induction and short-term surgical anesthesia [1] Group 1 - The new drug is classified as a Class 1 new drug for intravenous general anesthesia and was included in the "Major New Drug Creation" initiative in 2014 [1] - As of January 2026, the total R&D investment for this new drug is approximately 189 million yuan [1] - The projected sales for similar drugs in the domestic market in 2024 is around 4.238 billion yuan [1] Group 2 - Multiple approvals are required before the commercial production of the new drug, and the current acceptance does not have a significant impact on the company's performance at this stage [1]

Core Viewpoint - Recently, Fosun Pharma announced that its subsidiary, Fuhong Hanlin, received approval from the National Medical Products Administration to conduct Phase I clinical trials for HLX15-SC, a recombinant anti-CD38 fully human monoclonal antibody injection for the treatment of multiple myeloma [1] Group 1: Clinical Development - Fuhong Hanlin plans to conduct relevant clinical research for HLX15 in China once conditions are met [1] - HLX15 is a biosimilar to Daratumumab, with both subcutaneous (HLX15-SC) and intravenous (HLX15-IV) formulations intended for the treatment of multiple myeloma [1] Group 2: Financial Investment - As of January 2026, the company's cumulative R&D investment is approximately 192 million yuan [1] - According to the latest data, the global sales of Daratumumab formulations are expected to reach approximately 12.882 billion USD in 2024 [1]

Policy Developments - The National Health Commission announced the initiation of HPV vaccination for eligible girls starting in late February, aiming to provide free vaccination services to prevent high-risk HPV infections and reduce cervical cancer incidence [2]. Drug and Device Approvals - Fosun Pharma's subsidiary received approval for clinical trials of HLX15-SC, a monoclonal antibody for multiple myeloma treatment, with a cumulative R&D investment of approximately RMB 191.53 million expected by January 2026 [4]. - Hanyu Pharmaceutical received FDA approval for its acetate glatiramer injection, which treats relapsing multiple sclerosis, enhancing its product pipeline in the U.S. market [5]. Capital Markets - Guangji Pharmaceutical plans to raise up to RMB 600 million through a private placement of shares to repay loans and supplement working capital, pending necessary approvals [7]. - Bonasia and Zhejiang Jingxin Pharmaceutical submitted applications for listing on the Hong Kong Stock Exchange, with respective sponsors [8][9]. Clinical Innovations - A successful brain-machine interface surgery was performed in Guangxi, marking a significant advancement in clinical applications of this technology, with the market projected to reach RMB 3.2 billion by 2024, growing at 18.8% [10]. Research Developments - Researchers from the Wuhan Institute of Virology reported that the oral nucleoside prodrug VV261 effectively inhibits Chikungunya virus replication, supporting its potential new indications [11]. - Northwestern University scientists developed an advanced human spinal cord injury organoid model, providing a platform for testing new regenerative therapies [12]. Public Sentiment Alerts - McAudie announced a lawsuit against Shenyang Sixth People's Hospital over a contract dispute involving over RMB 319.82 million, with the case currently accepted by the court [14]. - The National Medical Insurance Administration listed 153 companies as "discredited," which may face restrictions on their products and services based on their credit ratings [15].

证券之星消息，2月12日南向资金减持32.3万股复星医药（02196.HK）。近5个交易日中，获南向资金减 持的有3天，累计净减持70.95万股。近20个交易日中，获南向资金增持的有12天，累计净增持64.55万 股。截至目前，南向资金持有复星医药（02196.HK）3.18亿股，占公司已发行普通股的57.61%。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2026-02-12 | 3.18亿 | -32.30万 | -0.10% | | 2026-02-11 | 3.18亿 | -65.20万 | -0.20% | | 2026-02-10 | 3.19亿 | 32.50万 | 0.10% | | 2026-02-09 | 3.19亿 | 17.90万 | 0.06% | | 2026-02-06 | 3.18亿 | -23.85万 | -0.07% | 上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经 营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊 ...

Group 1 - Fuda Alloy's controlling shareholder Wang Dawu plans to reduce his stake by up to 3% of the company's total shares, amounting to a maximum of 406.34 million shares, due to personal funding needs [1] - ST Songfa's subsidiary signed contracts for the construction of 17 vessels, with a total contract value between 1.6 billion to 1.8 billion USD [2] - Pairui Co. signed a technical cooperation agreement with a university to develop large-capacity power semiconductor devices and related power electronic modules, effective for three years [3] Group 2 - Shuangliang Energy indirectly participates in commercial aerospace projects, supplying heat exchangers for SpaceX's fuel production system, with orders totaling approximately 1.39 million CNY [4] - Hangya Technology plans to issue convertible bonds to raise up to 600 million CNY for various projects, including an intelligent manufacturing base in Malaysia [5] - Yuhua Development is publicly selling assets with a base price of 251 million CNY for residential properties [6] Group 3 - Penghui Energy plans to invest 2.1 billion CNY in a new battery production project in Zhengyang County, Henan Province, focusing on high-performance battery products [7] - Haige Communication's shareholder Yang Haizhou intends to reduce his stake by up to 0.1624% of the company's total shares [8] - Yaoshi Technology's controlling shareholder pledged 5.13% of shares to repay loans, with a pledge period from February 10, 2026, to February 2, 2027 [9][10] Group 4 - Hanyu Pharmaceutical received FDA approval for its drug Acetate Glatiramer Injection, used for treating relapsing multiple sclerosis [11] - Baiyao Tai's GoliMab Injection received EMA approval for various indications, including rheumatoid arthritis and ulcerative colitis [12] - Jiangxi Tungsten Equipment plans to issue A-shares to raise up to 1.882 billion CNY for acquisitions [13] Group 5 - Hesong New Materials expects to recognize asset impairment provisions between 23.6 million to 28.5 million CNY for 2025 [14] - ST Meichen's subsidiary is involved in two major lawsuits with a total amount of approximately 31.9 million CNY [15] - China Coal Energy reported a 7.3% year-on-year decline in coal sales for January 2026, with total sales of 20.05 million tons [16] Group 6 - Yida Co. plans to adjust its epoxy propylene derivative project, reducing the total investment from 845 million CNY to 642 million CNY [17] - Fosun Pharma's subsidiary received approval for a clinical trial of HLX15-SC for multiple myeloma treatment [18][19] - Yinfeng Communication's board members and executives have terminated their share reduction plan [20] Group 7 - Huazhong High-tech has waived its preferential purchase rights for a fund, extending the investment period from three to four years [21] - Warner Pharmaceuticals plans to participate in a national drug procurement program, with expected sales of 176 million CNY [22] - Changling Hydraulic announced a tender offer to acquire 12% of its shares at a price of 35.82 CNY per share [23] Group 8 - ST Chuan Zhi's stock may face delisting due to financial data falling below regulatory thresholds [24] - Tian Pharmaceutical and its subsidiaries are participating in a national drug procurement program, with expected sales of 323 million CNY [25] - China Metallurgical Group signed new contracts worth 73.65 billion CNY in January 2026 [26] Group 9 - Torus plans to invest 21.2 million CNY in a venture capital fund focused on artificial intelligence [27] - Shangwei Co. received a government subsidy of 1.764 million CNY, representing 10.79% of its net profit for 2024 [28] - Hanghua Co. reported a 21.97% decline in net profit for 2025, with total revenue of 1.249 billion CNY [29] Group 10 - Huaxia Bank reported a 1.72% decline in net profit for 2025, with total revenue of 91.914 billion CNY [30] - Guotou Fengle plans to transfer 51% of its stake in Hubei Fengle Ecological Fertilizer to optimize management [31] - Huaru Technology is co-investing in a fund with a total commitment of 20 million CNY [32] Group 11 - Jindike reported a loss of 173 million CNY for 2025, despite a 40.13% increase in revenue [33] - Zhenong Co. announced a 0.52% increase in shares held by a major shareholder [34] - Maike Audi plans to recognize asset impairment provisions of approximately 52.55 million CNY [35] Group 12 - Fuan Pharmaceutical's subsidiary is expected to be selected for a national drug procurement program, with projected sales of 680 million CNY [36] - Rundu Co. is participating in a national drug procurement program, with some products expected to be selected [37] - Changqing Co. has postponed its large-scale die-casting project to March 2027 due to customer requirements [38] Group 13 - Pan Asia Micro透 received a patent for a graphene-based automotive headlight defogging device [39] - Luan An Huan Neng reported a 17.1% increase in raw coal production for January 2026, totaling 5 million tons [40] - Guangji Pharmaceutical received a drug registration certificate for Mecobalamin Tablets [41] Group 14 - Ruifeng New Materials announced the resignation of its deputy general manager for personal reasons [42] - Zhiguang Electric's subsidiary signed a procurement contract for energy storage equipment worth 210.4 million CNY [43] - Youyan Powder Materials reported a 19.41% increase in net profit for 2025 [44] Group 15 - Jincheng reported a 22.2% increase in net profit for 2025, with total revenue of 253 million CNY [46]

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品獲臨床試驗批准的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2026 年2 月1 2 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士。 上 ...

证券代码：600196 股票简称：复星医药 编号：临 2026-022 上海复星医药（集团）股份有限公司 关于控股子公司药品获临床试验批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公 司上海复宏汉霖生物技术股份有限公司及其控股子公司（以下合称"复宏汉霖"） 收到国家药品监督管理局关于同意 HLX15-SC（即重组抗 CD38 全人单克隆抗体注射 液-皮下注射）用于多发性骨髓瘤治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件 具备后在中国境内（不包括港澳台地区，下同）开展该药品的相关临床研究。 二、HLX15 的基本信息及研究情况 HLX15（即重组抗 CD38 全人单克隆抗体）是本集团（即本公司及控股子公司/ 单位,下同）自主研发的达雷妥尤单抗生物类似药，包括皮下注射剂型 HLX15-SC 和 静脉注射剂型 HLX15-IV，拟用于多发性骨髓瘤（MM）等治疗。2024 年 6 月，在中国 男性健康受试者中开展的 HLX15-IVⅠ期临床研究已 ...